Assessment of the Cardiovascular Risk of Olmesartan Medoxomil-Based Treatment: Meta-Analysis of Individual Patient Data. - Wikidata - wikimedia - TriplyDB

Assessment of the Cardiovascular Risk of Olmesartan Medoxomil-Based Treatment: Meta-Analysis of Individual Patient Data.

Assessment of the Cardiovascular Risk of Olmesartan Medoxomil-Based Treatment: Meta-Analysis of Individual Patient Data.

http://www.wikidata.org/entity/Q31123979

about

Assessment of the Cardiovascular Risk of Olmesartan Medoxomil-Based Treatment: Meta-Analysis of Individual Patient Data.

http://www.wikidata.org/entity/Q31123979

description

2016 nî lūn-bûn

@nan

2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Assessment of the Cardiovascul ...... is of Individual Patient Data.

@ast

Assessment of the Cardiovascul ...... is of Individual Patient Data.

@en

type

label

Assessment of the Cardiovascul ...... is of Individual Patient Data.

@ast

Assessment of the Cardiovascul ...... is of Individual Patient Data.

@en

prefLabel

Assessment of the Cardiovascul ...... is of Individual Patient Data.

@ast

Assessment of the Cardiovascul ...... is of Individual Patient Data.

@en

P1433

Q31123979-59E2C1D1-A4D0-4EA5-B1B8-471C1518BAF2

P1476

Q31123979-555E12CF-61F6-45C7-AE6F-74C9C64099FF

P2093

Q31123979-451D3CEF-0FF9-42EF-B816-46CAC621D092

Q31123979-838FF5A0-796F-41E1-9A91-70C7BB549C77

Q31123979-8E93D34E-3041-4DA9-A522-EFD4A75AEF21

Q31123979-B04D8957-474E-45D2-93BC-2FBF12F795DB

Q31123979-D9434C37-8AED-4688-89EA-F8C175D0C4DB

P2860

Q31123979-0D37A570-A355-4879-A69B-40F34788930C

Q31123979-14262A89-4D9F-4721-8E55-04E55014CE7D

Q31123979-2D6FBDBF-2B34-4B2C-9CB4-233FEC841C86

Q31123979-3AA232FD-2481-4FBA-8EC2-E800596C55EE

Q31123979-3D449F60-4FCB-4E59-AC20-5354BF732E67

Q31123979-4C9E5D41-397C-4E03-8F9E-9F3E03C66F37

Q31123979-69C7AFCD-0F56-4192-BE2E-257053B011D0

Q31123979-6C2D2429-F4E9-46A4-87D5-4CCB45063983

Q31123979-C849BE8B-D867-429B-B60B-4B7E4C7412ED

Q31123979-F006DEBB-D0D1-44DC-8066-A7917E89FAE6

P2888

Q31123979-9C78F6D4-6129-4136-8998-2E588536D2EC

P304

Q31123979-67623A81-F949-4740-A017-FB9CAF02A669

P31

Q31123979-25456A88-6C9F-4884-9D5F-C90B95AD16FA

Q31123979-2e4f4fbd-bdca-4673-927c-d1a8eb5276af

P356

Q31123979-5C730716-081C-4FAB-8C41-4878C92DBFD8

P433

Q31123979-729CA3BE-48BE-4ADF-BA39-B10E588B91AA

P478

Q31123979-C7C32FB3-5E36-494E-8171-4E490096A58C

P577

Q31123979-32CCC882-CB30-4765-AAC2-CEC03B89EF1C

P6179

Q31123979-F3356D8E-7FA2-45D8-B7C9-781704B2CDEE

P698

Q31123979-F86A29F1-FB3E-421A-9F7C-DCE2C996FDCE

P356

S40256-016-0182-3

P1433

American journal of cardiovascular drugs

P1476

Assessment of the Cardiovascul ...... is of Individual Patient Data.

@en

P2093

Antonia C Wang

http://www.w3.org/2001/XMLSchema#string

Jennifer Schumi

http://www.w3.org/2001/XMLSchema#string

Nora Tu

http://www.w3.org/2001/XMLSchema#string

Paul-Egbert Reimitz

http://www.w3.org/2001/XMLSchema#string

Ulf Stellmacher

http://www.w3.org/2001/XMLSchema#string

P2860

Exact and efficient inference procedure for meta-analysis and its application to the analysis of independent 2 x 2 tables with all available data but without artificial continuity correction.

Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension

Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study.

Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study.

Olmesartan/amlodipine/hydrochlorothiazide in obese participants with hypertension: a TRINITY subanalysis

A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension.

Cardiac mortality in users of olmesartan, other angiotensin-receptor blockers and angiotensin-converting enzyme inhibitors.

Triple-Combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: the TRINITY randomized, double-blind, 12-week, parallel-group study.

Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study).

Cardiovascular and mortality risk in elderly Medicare beneficiaries treated with olmesartan versus other angiotensin receptor blockers.

P2888

s40256-016-0182-3

P304

427-437

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40256-016-0182-3

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1005132440

http://www.w3.org/2001/XMLSchema#string

P698

27565974

http://www.w3.org/2001/XMLSchema#string